Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Slides:

Advertisements

Similar presentations

Farxiga™ - Dapagliflozin

Advertisements

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.

Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.

Taieb V, et al. Value Health Nov;18(7):A598.

Neal B, et al. Diabetes Care 2015;38:403–411

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

Diabetic Dyslipidemia in Practice

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Empagliflozin (Jardiance®)

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

The Next Generation of Basal Insulins

Global Projections for Diabetes:

Updates on Outcomes for Novel T2D Therapies

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Updates Abound.

SGLT2 Inhibitors in the Modern Era: Why and Where?

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Tackling CV Risk in T2DM.

Managing Adverse Events With New Oral Therapies in CLL

Novel Approaches in T1D Management

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Novel Approaches to T1D Management

Antihyperglycemic Therapy

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

The Role of the Kidney in Glucose Control

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Dual SGLT1/SGLT2 Inhibition in T1D

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Glucose Management and Statin Therapy

Add-On Therapy to Insulin in T1DM Management

Patient Selection for Modern T2D Agents

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

2015 EASD In Review: CV Risk management in t2dm

Glucose Management and Statin Therapy

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Emerging Advances in Reducing Renal Complications of T2D

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors

Introduction/Overview

Intensive Therapy Reduces Diabetes Complications Rates

Variability in Time-Action Profile of Basal Insulins*

Intensive Insulin Therapy Is Limited by Hypoglycemia and Weight Gain

Rates of Glycemic Control in T1DM by Age Group

HbA1c Testing and Time-in-Range Outcome

Purpose of Adjunct Therapies in T1DM

Adjunct Therapies: Metformin

Pramlintide Meta-Analysis in T1DM: Adverse Events

ADJUNCT One Liraglutide + Insulin: Effect on HbA1c

T2DM Therapies for T1DM: SGLT Inhibitors

SGLT1/2 Inhibition

InTANDEM 2: Sotagliflozin in T1DM

Dapagliflozin DEPICT-1 and DEPICT-2: Study Design

DEPICT-1: Change in HbA1c Over 24 Weeks

DEPICT-2: Adjusted Mean Change in HbA1c

DEPICT-2: Time in Target Range

The EASE Clinical Development Program

EASE Trial: Efficacy Results

SGLT2 Inhibitors: Kidney Damage, Genital Infections, and Other AEs

Forest Plot: Events Suggestive of Genital Infections in Patients With T2DM Receiving SGLT2 Inhibitors

Safety Issues: EASE, InTANDEM

DKA Risk With SGLT2 Inhibitors

Managing the DKA Risk

Managing the DKA Risk (cont)

Managing the DKA Risk (cont)

STICH Protocol

Summary and Conclusions

Abbreviations

Abbreviations (cont)